Effect of Retatrutide Compared With Semaglutide in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

This is a registry record, not a result. A trial being listed, recruiting or completed says nothing by itself about whether the compound works or is safe.

Registry numberNCT06260722
StatusActive not recruiting
PhasePhase 3
SponsorEli Lilly and Company
Enrollment1,250 participants
DesignInterventional, Randomized, Parallel, Masking: None
ConditionsDiabetes Mellitus, Type 2
InterventionsRetatrutide; Semaglutide
StartFeb 21, 2024
Primary completionAug 27, 2026
Study completionFeb 2027
Results postedNot yet
Registry last updatedSep 28, 2026

Compounds on this site that cite this trial

What the registry says the trial is about

The purpose of this study is to investigate the efficacy and safety of retatrutide compared with semaglutide in participants with Type 2 Diabetes and inadequate glycemic control with metformin with or without sodium-glucose cotransporter-2 inhibitor (SGLT2i). The study will last about 26 months and may include up to 24 visits.

Primary outcomes

These are what the trial was designed to measure first. They are registered in advance, which is what makes a later result checkable.

Outcome measureTime frame
Change from Baseline in Hemoglobin A1c (HbA1c) (%)Baseline, Week 80

12 secondary outcomes also registered. See the registry record for the full list.

Source: ClinicalTrials.gov (U.S. National Library of Medicine). Last checked against the registry on Nov 17, 2026. See the trial changes feed for what has changed recently.

Share thisFacebookXEmail